ANI Pharma's Purified Cortrophin Gel Application Under FDA Review

by Vandana Singh, Benzinga Editor

August 31, 2021 9:57 AM | 27 seconds read |

The FDA has accepted ANI Pharmaceuticals Inc's ANIP supplemental marketing application for Purified Cortrophin Gel.
The application seeks approval for multiple indications, including multiple sclerosis, rheumatoid arthritis, and nephrotic syndrome.
Prescription Drug User Fee Act's target action date is October 29.
Related content: Benzinga's Full FDA Calendar.
Price Action: ANIP shares are 11.20% at $30.46 during the premarket session on the last check Tuesday.

Posted In: Biotech Long Ideas News Health Care Small Cap FDA Movers Trading Ideas General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.